Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 13/20 | 0.67 |
| ▸ | MTTP | P55157 | 12/20 | 0.67 |
| ▸ | SMO | Q99835 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513042 | 1.00 | APOB (0.67) | APOBMTTPSMOGAAKDM4E | |
| SCHEMBL6198944 | 0.86 | MTTP (0.78) | APOBMTTPSMO | |
| SCHEMBL6195985 | 0.86 | MTTP (0.78) | APOBMTTPSMO | |
| SCHEMBL7760794 | 0.83 | APOB (0.76) | APOBMTTPSMO | |
| SCHEMBL7760803 | 0.83 | APOB (0.76) | APOBMTTPSMO | |
| SCHEMBL8208177 | 0.82 | APOB (0.56) | APOBMTTPSMOGAAKDM4E | |
| SCHEMBL8208303 | 0.79 | APOB (0.62) | APOBMTTPSMOGAAKDM4E | |
| SCHEMBL2582528 | 0.79 | MAPKAPK2 (0.64) | APOBMTTPGAAKDM4EALDH1A1 | |
| SCHEMBL7761722 | 0.79 | APOB (0.76) | APOBMTTPSMO | |
| SCHEMBL7764346 | 0.78 | APOB (1.00) | APOBMTTPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259484-B1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2005-05-18 | — | — | EP | disclosed |
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2003-06-12 | — | — | US | disclosed |
| EP-1259484-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001053260-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | APOB, CETP, MTTP | APOB 1/4885MTTP 3/4885SMO 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.